Glaukos Corporation Announces Second Quarter 2022 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2022. Key highl...

Related Keywords

Chris Lewis ,Thomas Burns ,Corneal Health ,Avedro Inc ,Veena Delivery Systems Inc ,Glaukos Corporation ,Exchange Commission ,Intratus Inc ,International Glaucoma ,Investor Relations Corporate Affairs ,Veena Delivery Systems ,Investor Relations ,Quarterly Summary ,Micro Invasive Glaucoma Surgery ,Quarterly Report ,Investor Section ,Regarding Use ,Generally Accepted Accounting Principles ,Corporate Affairs ,